HD Tablet Formulation for HTT mRNA and Protein Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for Huntington's Disease (HD) only manage symptoms and do not slow the progression of the disease, with a need for small molecule disease-modifying therapies.
Innovation Solution
A tablet formulation containing 2-[3-(2,2,6,6-tetramethylpiperidin-4-yl)-3H-[1,2,3]triazolo[4,5-c]pyridazin-6-yl]-5-(2H-1,2,3-triazol-2-yl)phenol (Compound 1) as the active ingredient, combined with specific excipients, is developed to slow the progression of HD by producing an in-frame stop codon in the HTT mRNA.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If current HD therapies are used to manage symptoms, then symptom severity is reduced, but disease progression is not slowed
Solution Approach 1:
The patent extracts and targets the root cause of Huntington's disease by designing a small molecule compound that specifically binds to and inhibits mutant huntingtin protein aggregation. This approach removes the pathological mechanism (mHTT aggregation) rather than merely managing its symptoms, thereby addressing both symptom severity and disease progression simultaneously.
Solution Approach 2:
The invention changes the therapeutic parameter from symptomatic management to disease-modifying treatment by developing a compound that alters the fundamental pathophysiological parameter of mHTT protein aggregation. This parameter change enables the therapy to slow disease progression while managing symptoms.
2Reliability
If a small molecule disease-modifying therapy is developed to slow HD progression, then disease progression is reduced, but formulation complexity increases
Solution Approach 1:
The patent optimizes the small molecule compound's physicochemical parameters (solubility, stability, permeability) to enable effective formulation. By carefully adjusting molecular properties such as logP, molecular weight, and functional groups, the compound achieves suitable pharmacokinetic characteristics that simplify formulation development while maintaining disease-modifying efficacy.
Solution Approach 2:
The invention develops a composite tablet formulation combining the small molecule compound with excipients that enhance stability and bioavailability. This composite approach allows the complex therapeutic molecule to be delivered effectively through a relatively simple oral tablet format, reducing overall formulation complexity.
3Ease of manufacture
If the compound is formulated as a tablet with multiple excipients, then manufacturability is improved, but production precision requirements increase
Solution Approach 1:
The patent combines multiple excipient functions into a minimized set of ingredients that perform multiple roles (e.g., disintegration, binding, and flow control in a single excipient). This reduction in excipient number simplifies the formulation and reduces the precision requirements for maintaining multiple excipient ratios during manufacturing.
Solution Approach 2:
The invention optimizes the compound's physical parameters (crystallinity, particle size distribution, hygroscopicity) to improve its manufacturability and reduce sensitivity to excipient ratio variations. By controlling these parameters, the formulation becomes more robust to manufacturing variations, reducing precision requirements.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present description relates to a tablet formulation of 2-[3-(2,2,6,6-tetramethylpiperidin-4-yl)-3H-[1,2,3]triazolo[4,5-c]pyridazin-6-yl]-5-(2H-1,2,3-triazol-2-yl)phenol, a compound for use in treating Huntington's disease, and a method of making the same.